AUM Biosciences and HANDOK Presented Phase 1 Data for AUM-601 at ESMO Targeted Anticancer Therapies Congress 2022

SINGAPORE and SEOUL, South Korea, April 19 (Korea Bizwire) – AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing novel targeted oncology therapeutics, Handok Inc. [002390: KOSPI] (“Handok”), a leading innovation-driven pharmaceutical / healthcare company in Korea, and CMG Pharmaceutical Co. Ltd. [058820: KOSDAQ] (“CMG”) today jointly announced Phase 1 data for AUM-601 (CHC2014), a selective second generation [...]